The growth of Endoscopic Retrograde Cholangiopancreatography Market is majorly attributed to factors such as the rising incidence of cancer, increasing investments by governments and healthcare organizations to improve endoscopy research, growing focus on investments by hospitals for advanced endoscopy instruments, and the increasing preference for minimally invasive surgeries. On the other hand, the high costs of endoscopic retrograde cholangiopancreatography devices, the development of other procedures like EUS and MRCP, and the shortage of trained physicians and endoscopists are factors expected to restrain the market growth to a certain extent.
The global endoscopic retrograde cholangiopancreatography market is projected to reach USD 2.0 billion by 2026 from USD 1.3
billion in 2021, at a CAGR of 9.6% during the forecast period.
Download PDF Brochure: -https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=170242954
Market Segmentation
Based on products, the endoscopic retrograde
cholangiopancreatography market has been segmented into endoscopes, endotherapy
devices, visualization systems, energy devices, and others. The factors
attributing to the large revenue of the endotherapy devices segment include the
growing preference for minimally invasive surgeries and the increasing
prevalence of gastrointestinal conditions.
In the endotherapy devices segment, sphincterotomes accounted for the largest market share during the forecast period. This can be attributed to the increasing incidence of pancreatic duct and bile duct stones and the growing geriatric population leading to an increase in biliary disorders.
Regional
Analysis:
North
America accounted for the largest share of the ERCP
market in 2020. The increasing prevalence of cancer, high investments by
hospitals to purchase new ERCP equipment, and a strong focus on research
activities to improve endoscopy techniques are the major factor contributing to
this.
Request Sample Pages: - https://www.marketsandmarkets.com/requestsampleNew.asp?id=170242954
Top Key Players:
The major players in the global endoscopic
retrograde cholangiopancreatography market include Olympus Corporation (Japan),
CONMED Corporation (US), Fujifilm Holdings Corporation (Japan),
HOYA Corporation (Japan), KARL STORZ SE &
Co. KG (Germany),
Ambu A/S (Denmark),
Boston Scientific Corporation (US), Johnson & Johnson (US), Medtronic, PLC
(Ireland),
Cook Medical (US), and B. Braun Melsungen AG (Germany).
No comments:
Post a Comment